Evidence map›Paper›PMID 25151563›Full record

ReviewInfectious disease clinics of North America2014

Antiretroviral therapy: when to start.

Christopher J Sellers, David A Wohl

Abstract readReview
In one paragraph

Review in Infectious disease clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Christopher J SellersDivision of Infectious Diseases, School of Medicine, University of North Carolina, 130 Mason Farm Road, CB# 7030, Chapel Hill, NC 27599-7030, USA.
David A WohlDivision of Infectious Diseases, School of Medicine, University of North Carolina, 130 Mason Farm Road, CB# 7030, Chapel Hill, NC 27599-7030, USA. Electronic address: david_wohl@med.unc.edu.

Funding

Training in Infectious Disease Epidemiology (TIDE)T32AI070114 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Brian W Pence · 2007 to 2026
$4.0M
Mentoring New Investigators in Criminal Justice HIV Prevention and TreatmentK24DA037101 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WOHL, DAVID A · 2014 to 2018
$911k
NIAID NIH HHS 5T32AI070114-08NIAID NIH HHS T32 AI070114NIDA NIH HHS K24 DA037101
6 · The paper itself

Abstract

In this article, the scientific evidence and professional guidelines regarding the timing of antiretroviral therapy initiation are reviewed, with discussion of the increasingly persuasive evidence in favor of starting treatment early in the course of human immunodeficiency virus disease.

Indexed as

Anti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountHIV InfectionsHumansPractice Guidelines as TopicTime FactorsAnti-Retroviral AgentsAntiretroviralCD4Human immunodeficiency virusInitiationStartTherapyTiming

Identifiers

PMID25151563
PMCPMC4369085

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.